CN113316818A - 新生抗原的鉴定方法 - Google Patents
新生抗原的鉴定方法 Download PDFInfo
- Publication number
- CN113316818A CN113316818A CN202080008090.2A CN202080008090A CN113316818A CN 113316818 A CN113316818 A CN 113316818A CN 202080008090 A CN202080008090 A CN 202080008090A CN 113316818 A CN113316818 A CN 113316818A
- Authority
- CN
- China
- Prior art keywords
- tumor
- sequencing
- gene
- mutation
- somatic
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 238000000034 method Methods 0.000 title claims abstract description 109
- 206010028980 Neoplasm Diseases 0.000 claims abstract description 198
- 206010069754 Acquired gene mutation Diseases 0.000 claims description 129
- 230000037439 somatic mutation Effects 0.000 claims description 129
- 238000012163 sequencing technique Methods 0.000 claims description 98
- 108090000623 proteins and genes Proteins 0.000 claims description 67
- 108090000765 processed proteins & peptides Proteins 0.000 claims description 54
- 230000035772 mutation Effects 0.000 claims description 43
- 102000004196 processed proteins & peptides Human genes 0.000 claims description 34
- 150000001413 amino acids Chemical class 0.000 claims description 30
- 230000014509 gene expression Effects 0.000 claims description 29
- 238000012216 screening Methods 0.000 claims description 28
- 230000006870 function Effects 0.000 claims description 20
- 239000000427 antigen Substances 0.000 claims description 18
- 125000003275 alpha amino acid group Chemical group 0.000 claims description 17
- 108091007433 antigens Proteins 0.000 claims description 17
- 102000036639 antigens Human genes 0.000 claims description 17
- 108700028369 Alleles Proteins 0.000 claims description 16
- 238000007482 whole exome sequencing Methods 0.000 claims description 13
- 201000011510 cancer Diseases 0.000 claims description 11
- 229940028444 muse Drugs 0.000 claims description 11
- GMVPRGQOIOIIMI-DWKJAMRDSA-N prostaglandin E1 Chemical compound CCCCC[C@H](O)\C=C\[C@H]1[C@H](O)CC(=O)[C@@H]1CCCCCCC(O)=O GMVPRGQOIOIIMI-DWKJAMRDSA-N 0.000 claims description 11
- 102000004245 Proteasome Endopeptidase Complex Human genes 0.000 claims description 8
- 108090000708 Proteasome Endopeptidase Complex Proteins 0.000 claims description 8
- 230000001613 neoplastic effect Effects 0.000 claims description 8
- 238000004949 mass spectrometry Methods 0.000 claims description 7
- 238000003860 storage Methods 0.000 claims description 6
- 101150075764 CD4 gene Proteins 0.000 claims description 5
- 229940076838 Immune checkpoint inhibitor Drugs 0.000 claims description 3
- 102000037984 Inhibitory immune checkpoint proteins Human genes 0.000 claims description 3
- 108091008026 Inhibitory immune checkpoint proteins Proteins 0.000 claims description 3
- 239000012274 immune-checkpoint protein inhibitor Substances 0.000 claims description 3
- 230000029087 digestion Effects 0.000 claims description 2
- 238000001976 enzyme digestion Methods 0.000 claims description 2
- 238000001819 mass spectrum Methods 0.000 claims description 2
- 108700026220 vif Genes Proteins 0.000 claims description 2
- 229960005486 vaccine Drugs 0.000 abstract description 13
- 210000001744 T-lymphocyte Anatomy 0.000 abstract description 6
- 238000009169 immunotherapy Methods 0.000 abstract description 4
- 238000002659 cell therapy Methods 0.000 abstract description 3
- 210000004027 cell Anatomy 0.000 description 66
- 210000001519 tissue Anatomy 0.000 description 64
- 241000699670 Mus sp. Species 0.000 description 24
- 238000004458 analytical method Methods 0.000 description 23
- 238000001514 detection method Methods 0.000 description 21
- 238000004422 calculation algorithm Methods 0.000 description 15
- 241000699666 Mus <mouse, genus> Species 0.000 description 13
- 108091036414 Polyinosinic:polycytidylic acid Proteins 0.000 description 12
- 210000005259 peripheral blood Anatomy 0.000 description 11
- 239000011886 peripheral blood Substances 0.000 description 11
- 238000001914 filtration Methods 0.000 description 10
- 241000282414 Homo sapiens Species 0.000 description 9
- 238000011282 treatment Methods 0.000 description 9
- 238000003776 cleavage reaction Methods 0.000 description 8
- 239000012634 fragment Substances 0.000 description 8
- 102000004169 proteins and genes Human genes 0.000 description 8
- 230000007017 scission Effects 0.000 description 8
- 238000007920 subcutaneous administration Methods 0.000 description 8
- 238000011081 inoculation Methods 0.000 description 7
- 239000002609 medium Substances 0.000 description 7
- 210000004988 splenocyte Anatomy 0.000 description 7
- 230000004614 tumor growth Effects 0.000 description 7
- 239000002671 adjuvant Substances 0.000 description 6
- 239000003814 drug Substances 0.000 description 6
- 230000028993 immune response Effects 0.000 description 6
- 108020004414 DNA Proteins 0.000 description 5
- 238000005516 engineering process Methods 0.000 description 5
- 238000003114 enzyme-linked immunosorbent spot assay Methods 0.000 description 5
- 238000012165 high-throughput sequencing Methods 0.000 description 5
- 239000008194 pharmaceutical composition Substances 0.000 description 5
- 230000002829 reductive effect Effects 0.000 description 5
- 210000004881 tumor cell Anatomy 0.000 description 5
- 102100037850 Interferon gamma Human genes 0.000 description 4
- 108010074328 Interferon-gamma Proteins 0.000 description 4
- 241001465754 Metazoa Species 0.000 description 4
- 238000003559 RNA-seq method Methods 0.000 description 4
- 230000002163 immunogen Effects 0.000 description 4
- 201000007270 liver cancer Diseases 0.000 description 4
- 208000014018 liver neoplasm Diseases 0.000 description 4
- 239000000203 mixture Substances 0.000 description 4
- 238000007481 next generation sequencing Methods 0.000 description 4
- 239000002773 nucleotide Substances 0.000 description 4
- 125000003729 nucleotide group Chemical group 0.000 description 4
- 229920001184 polypeptide Polymers 0.000 description 4
- 238000003908 quality control method Methods 0.000 description 4
- 230000003248 secreting effect Effects 0.000 description 4
- 101100428022 Arabidopsis thaliana UTR3 gene Proteins 0.000 description 3
- 101150059668 Bard1 gene Proteins 0.000 description 3
- IAZDPXIOMUYVGZ-UHFFFAOYSA-N Dimethylsulphoxide Chemical compound CS(C)=O IAZDPXIOMUYVGZ-UHFFFAOYSA-N 0.000 description 3
- 101000820585 Homo sapiens SUN domain-containing ossification factor Proteins 0.000 description 3
- 101000673946 Homo sapiens Synaptotagmin-like protein 1 Proteins 0.000 description 3
- 102000043129 MHC class I family Human genes 0.000 description 3
- 108091054437 MHC class I family Proteins 0.000 description 3
- 101100453133 Saccharomyces cerevisiae (strain ATCC 204508 / S288c) ISY1 gene Proteins 0.000 description 3
- 102100040541 Synaptotagmin-like protein 1 Human genes 0.000 description 3
- 101150007199 UTR5 gene Proteins 0.000 description 3
- 108020004417 Untranslated RNA Proteins 0.000 description 3
- 102000039634 Untranslated RNA Human genes 0.000 description 3
- 230000004075 alteration Effects 0.000 description 3
- 238000004590 computer program Methods 0.000 description 3
- 238000013461 design Methods 0.000 description 3
- 201000010099 disease Diseases 0.000 description 3
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 3
- 239000003937 drug carrier Substances 0.000 description 3
- 230000000694 effects Effects 0.000 description 3
- 102000054766 genetic haplotypes Human genes 0.000 description 3
- 108020004999 messenger RNA Proteins 0.000 description 3
- 230000003285 pharmacodynamic effect Effects 0.000 description 3
- 230000035945 sensitivity Effects 0.000 description 3
- 210000001082 somatic cell Anatomy 0.000 description 3
- 210000000952 spleen Anatomy 0.000 description 3
- 238000011144 upstream manufacturing Methods 0.000 description 3
- 206010000830 Acute leukaemia Diseases 0.000 description 2
- 206010005003 Bladder cancer Diseases 0.000 description 2
- 206010006187 Breast cancer Diseases 0.000 description 2
- 208000026310 Breast neoplasm Diseases 0.000 description 2
- 102100036178 Centrosomal protein of 192 kDa Human genes 0.000 description 2
- 206010008342 Cervix carcinoma Diseases 0.000 description 2
- 108091026890 Coding region Proteins 0.000 description 2
- 206010009944 Colon cancer Diseases 0.000 description 2
- 101150102768 Dhodh gene Proteins 0.000 description 2
- 238000011510 Elispot assay Methods 0.000 description 2
- 208000000461 Esophageal Neoplasms Diseases 0.000 description 2
- 108700024394 Exon Proteins 0.000 description 2
- 208000032612 Glial tumor Diseases 0.000 description 2
- 206010018338 Glioma Diseases 0.000 description 2
- 208000002250 Hematologic Neoplasms Diseases 0.000 description 2
- 208000008839 Kidney Neoplasms Diseases 0.000 description 2
- 206010023825 Laryngeal cancer Diseases 0.000 description 2
- 206010058467 Lung neoplasm malignant Diseases 0.000 description 2
- 206010025323 Lymphomas Diseases 0.000 description 2
- 108700018351 Major Histocompatibility Complex Proteins 0.000 description 2
- 208000001894 Nasopharyngeal Neoplasms Diseases 0.000 description 2
- 206010061306 Nasopharyngeal cancer Diseases 0.000 description 2
- 108091028043 Nucleic acid sequence Proteins 0.000 description 2
- 206010030155 Oesophageal carcinoma Diseases 0.000 description 2
- 206010033128 Ovarian cancer Diseases 0.000 description 2
- 206010061535 Ovarian neoplasm Diseases 0.000 description 2
- 206010061902 Pancreatic neoplasm Diseases 0.000 description 2
- 206010060862 Prostate cancer Diseases 0.000 description 2
- 208000000236 Prostatic Neoplasms Diseases 0.000 description 2
- 208000015634 Rectal Neoplasms Diseases 0.000 description 2
- 206010038389 Renal cancer Diseases 0.000 description 2
- 101150046285 Sdcbp gene Proteins 0.000 description 2
- 208000005718 Stomach Neoplasms Diseases 0.000 description 2
- 102100035003 Synaptotagmin-like protein 5 Human genes 0.000 description 2
- 101150057813 Sytl5 gene Proteins 0.000 description 2
- 102100034922 T-cell surface glycoprotein CD8 alpha chain Human genes 0.000 description 2
- 208000007097 Urinary Bladder Neoplasms Diseases 0.000 description 2
- 208000006105 Uterine Cervical Neoplasms Diseases 0.000 description 2
- 101150004074 Vps33a gene Proteins 0.000 description 2
- -1 anti-PD1 Proteins 0.000 description 2
- 230000000259 anti-tumor effect Effects 0.000 description 2
- 238000004364 calculation method Methods 0.000 description 2
- 239000006285 cell suspension Substances 0.000 description 2
- 201000010881 cervical cancer Diseases 0.000 description 2
- 230000001684 chronic effect Effects 0.000 description 2
- 208000024207 chronic leukemia Diseases 0.000 description 2
- 208000029742 colonic neoplasm Diseases 0.000 description 2
- 201000004101 esophageal cancer Diseases 0.000 description 2
- 206010017758 gastric cancer Diseases 0.000 description 2
- PCHJSUWPFVWCPO-UHFFFAOYSA-N gold Chemical compound [Au] PCHJSUWPFVWCPO-UHFFFAOYSA-N 0.000 description 2
- 230000012010 growth Effects 0.000 description 2
- 239000001963 growth medium Substances 0.000 description 2
- 201000010536 head and neck cancer Diseases 0.000 description 2
- 208000014829 head and neck neoplasm Diseases 0.000 description 2
- 206010073071 hepatocellular carcinoma Diseases 0.000 description 2
- 231100000844 hepatocellular carcinoma Toxicity 0.000 description 2
- 230000005847 immunogenicity Effects 0.000 description 2
- 238000000338 in vitro Methods 0.000 description 2
- 230000002452 interceptive effect Effects 0.000 description 2
- 201000010982 kidney cancer Diseases 0.000 description 2
- 206010023841 laryngeal neoplasm Diseases 0.000 description 2
- 201000005202 lung cancer Diseases 0.000 description 2
- 208000020816 lung neoplasm Diseases 0.000 description 2
- 208000015486 malignant pancreatic neoplasm Diseases 0.000 description 2
- 238000004519 manufacturing process Methods 0.000 description 2
- 239000011159 matrix material Substances 0.000 description 2
- 201000001441 melanoma Diseases 0.000 description 2
- 238000002156 mixing Methods 0.000 description 2
- 238000010172 mouse model Methods 0.000 description 2
- 230000003287 optical effect Effects 0.000 description 2
- 201000008968 osteosarcoma Diseases 0.000 description 2
- 201000002528 pancreatic cancer Diseases 0.000 description 2
- 208000008443 pancreatic carcinoma Diseases 0.000 description 2
- 239000002244 precipitate Substances 0.000 description 2
- 230000002265 prevention Effects 0.000 description 2
- 230000008569 process Effects 0.000 description 2
- 239000000047 product Substances 0.000 description 2
- 206010038038 rectal cancer Diseases 0.000 description 2
- 201000001275 rectum cancer Diseases 0.000 description 2
- 238000007480 sanger sequencing Methods 0.000 description 2
- 230000028327 secretion Effects 0.000 description 2
- 241000894007 species Species 0.000 description 2
- 230000003595 spectral effect Effects 0.000 description 2
- 210000004989 spleen cell Anatomy 0.000 description 2
- 230000000638 stimulation Effects 0.000 description 2
- 201000011549 stomach cancer Diseases 0.000 description 2
- 239000000126 substance Substances 0.000 description 2
- 230000020382 suppression by virus of host antigen processing and presentation of peptide antigen via MHC class I Effects 0.000 description 2
- 238000003786 synthesis reaction Methods 0.000 description 2
- 238000012360 testing method Methods 0.000 description 2
- 201000005112 urinary bladder cancer Diseases 0.000 description 2
- 101150092939 Abcc4 gene Proteins 0.000 description 1
- 101150111062 C gene Proteins 0.000 description 1
- 102000008203 CTLA-4 Antigen Human genes 0.000 description 1
- 108010021064 CTLA-4 Antigen Proteins 0.000 description 1
- 229940045513 CTLA4 antagonist Drugs 0.000 description 1
- 101100198345 Caenorhabditis elegans rnf-121 gene Proteins 0.000 description 1
- 241000282693 Cercopithecidae Species 0.000 description 1
- 238000002965 ELISA Methods 0.000 description 1
- 201000003741 Gastrointestinal carcinoma Diseases 0.000 description 1
- 101150101098 HIPK1 gene Proteins 0.000 description 1
- 102000008949 Histocompatibility Antigens Class I Human genes 0.000 description 1
- 108010088652 Histocompatibility Antigens Class I Proteins 0.000 description 1
- 241000282412 Homo Species 0.000 description 1
- 101001117317 Homo sapiens Programmed cell death 1 ligand 1 Proteins 0.000 description 1
- 101000658110 Homo sapiens Synaptotagmin-like protein 2 Proteins 0.000 description 1
- 101000658112 Homo sapiens Synaptotagmin-like protein 3 Proteins 0.000 description 1
- 101150017040 I gene Proteins 0.000 description 1
- 101150062179 II gene Proteins 0.000 description 1
- 108010002350 Interleukin-2 Proteins 0.000 description 1
- 102000043131 MHC class II family Human genes 0.000 description 1
- 108091054438 MHC class II family Proteins 0.000 description 1
- 241000124008 Mammalia Species 0.000 description 1
- 101100180990 Mus musculus Khnyn gene Proteins 0.000 description 1
- 101100091963 Mus musculus Polrmt gene Proteins 0.000 description 1
- 101100309367 Mus musculus Sec23ip gene Proteins 0.000 description 1
- 101100312652 Mus musculus Sytl4 gene Proteins 0.000 description 1
- 101100206736 Mus musculus Tiam1 gene Proteins 0.000 description 1
- 108700026244 Open Reading Frames Proteins 0.000 description 1
- 102000007079 Peptide Fragments Human genes 0.000 description 1
- 108010033276 Peptide Fragments Proteins 0.000 description 1
- 241000288906 Primates Species 0.000 description 1
- 102100024216 Programmed cell death 1 ligand 1 Human genes 0.000 description 1
- 241000700159 Rattus Species 0.000 description 1
- 108091081062 Repeated sequence (DNA) Proteins 0.000 description 1
- 241000283984 Rodentia Species 0.000 description 1
- 101150088385 SLC25A37 gene Proteins 0.000 description 1
- 102100035007 Synaptotagmin-like protein 2 Human genes 0.000 description 1
- 102100035001 Synaptotagmin-like protein 3 Human genes 0.000 description 1
- 230000002159 abnormal effect Effects 0.000 description 1
- 239000008186 active pharmaceutical agent Substances 0.000 description 1
- 230000003044 adaptive effect Effects 0.000 description 1
- 230000002411 adverse Effects 0.000 description 1
- 239000003963 antioxidant agent Substances 0.000 description 1
- 238000003556 assay Methods 0.000 description 1
- 230000000386 athletic effect Effects 0.000 description 1
- 238000013476 bayesian approach Methods 0.000 description 1
- 239000011230 binding agent Substances 0.000 description 1
- 230000015572 biosynthetic process Effects 0.000 description 1
- 239000000872 buffer Substances 0.000 description 1
- 239000007853 buffer solution Substances 0.000 description 1
- 230000004663 cell proliferation Effects 0.000 description 1
- 238000005119 centrifugation Methods 0.000 description 1
- 230000008859 change Effects 0.000 description 1
- 238000006243 chemical reaction Methods 0.000 description 1
- 238000002512 chemotherapy Methods 0.000 description 1
- 238000010835 comparative analysis Methods 0.000 description 1
- 238000005094 computer simulation Methods 0.000 description 1
- 238000011443 conventional therapy Methods 0.000 description 1
- 238000013480 data collection Methods 0.000 description 1
- 230000007547 defect Effects 0.000 description 1
- 238000011161 development Methods 0.000 description 1
- 239000007884 disintegrant Substances 0.000 description 1
- 229940079593 drug Drugs 0.000 description 1
- 238000011156 evaluation Methods 0.000 description 1
- 230000003203 everyday effect Effects 0.000 description 1
- 238000002474 experimental method Methods 0.000 description 1
- 239000000945 filler Substances 0.000 description 1
- 238000009472 formulation Methods 0.000 description 1
- 238000012268 genome sequencing Methods 0.000 description 1
- 210000004602 germ cell Anatomy 0.000 description 1
- 230000036541 health Effects 0.000 description 1
- 201000005787 hematologic cancer Diseases 0.000 description 1
- 210000000987 immune system Anatomy 0.000 description 1
- 238000002649 immunization Methods 0.000 description 1
- 230000003053 immunization Effects 0.000 description 1
- 238000002513 implantation Methods 0.000 description 1
- 230000001939 inductive effect Effects 0.000 description 1
- 230000005764 inhibitory process Effects 0.000 description 1
- 230000010354 integration Effects 0.000 description 1
- 201000002313 intestinal cancer Diseases 0.000 description 1
- 238000007912 intraperitoneal administration Methods 0.000 description 1
- 239000007928 intraperitoneal injection Substances 0.000 description 1
- 239000007951 isotonicity adjuster Substances 0.000 description 1
- 101150047102 kpnb1 gene Proteins 0.000 description 1
- 101150043067 lcp1 gene Proteins 0.000 description 1
- 210000000265 leukocyte Anatomy 0.000 description 1
- 230000000670 limiting effect Effects 0.000 description 1
- 239000007788 liquid Substances 0.000 description 1
- 239000000314 lubricant Substances 0.000 description 1
- 239000003550 marker Substances 0.000 description 1
- 238000005259 measurement Methods 0.000 description 1
- 239000012452 mother liquor Substances 0.000 description 1
- 230000008520 organization Effects 0.000 description 1
- 229940023041 peptide vaccine Drugs 0.000 description 1
- 239000000843 powder Substances 0.000 description 1
- 238000002360 preparation method Methods 0.000 description 1
- 230000001850 reproductive effect Effects 0.000 description 1
- 238000011160 research Methods 0.000 description 1
- 230000000717 retained effect Effects 0.000 description 1
- 238000000926 separation method Methods 0.000 description 1
- 210000002966 serum Anatomy 0.000 description 1
- 201000002314 small intestine cancer Diseases 0.000 description 1
- 101150000485 snd1 gene Proteins 0.000 description 1
- 239000007787 solid Substances 0.000 description 1
- 239000002904 solvent Substances 0.000 description 1
- 230000003393 splenic effect Effects 0.000 description 1
- 239000003381 stabilizer Substances 0.000 description 1
- 238000010561 standard procedure Methods 0.000 description 1
- 239000011550 stock solution Substances 0.000 description 1
- 239000007929 subcutaneous injection Substances 0.000 description 1
- 238000010254 subcutaneous injection Methods 0.000 description 1
- 239000004094 surface-active agent Substances 0.000 description 1
- 238000001356 surgical procedure Methods 0.000 description 1
- 239000000725 suspension Substances 0.000 description 1
- 230000008685 targeting Effects 0.000 description 1
- 238000002560 therapeutic procedure Methods 0.000 description 1
- 229940021747 therapeutic vaccine Drugs 0.000 description 1
- 230000002110 toxicologic effect Effects 0.000 description 1
- 231100000759 toxicological effect Toxicity 0.000 description 1
- 238000010200 validation analysis Methods 0.000 description 1
- 238000005406 washing Methods 0.000 description 1
Images
Classifications
-
- G—PHYSICS
- G16—INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR SPECIFIC APPLICATION FIELDS
- G16B—BIOINFORMATICS, i.e. INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR GENETIC OR PROTEIN-RELATED DATA PROCESSING IN COMPUTATIONAL MOLECULAR BIOLOGY
- G16B30/00—ICT specially adapted for sequence analysis involving nucleotides or amino acids
Landscapes
- Physics & Mathematics (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Analytical Chemistry (AREA)
- Biophysics (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Health & Medical Sciences (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Bioinformatics & Computational Biology (AREA)
- Biotechnology (AREA)
- Evolutionary Biology (AREA)
- General Health & Medical Sciences (AREA)
- Medical Informatics (AREA)
- Spectroscopy & Molecular Physics (AREA)
- Theoretical Computer Science (AREA)
- Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
Abstract
本发明涉及肿瘤免疫治疗的领域。具体而言，本发明提供了患者中肿瘤特异性新生抗原的鉴定方法和装置。通过本发明的方法或装置鉴定的新生抗原可用于开发针对所述肿瘤的疫苗或T细胞疗法。
Description
PCT国内申请，说明书已公开。
Claims (26)
- PCT国内申请，权利要求书已公开。
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201910198582.1A CN111696628A (zh) | 2019-03-15 | 2019-03-15 | 新生抗原的鉴定方法 |
| CN2019101985821 | 2019-03-15 | ||
| PCT/CN2020/079131 WO2020187143A1 (zh) | 2019-03-15 | 2020-03-13 | 新生抗原的鉴定方法 |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| CN113316818A true CN113316818A (zh) | 2021-08-27 |
| CN113316818B CN113316818B (zh) | 2024-04-02 |
Family
ID=72475381
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN201910198582.1A Pending CN111696628A (zh) | 2019-03-15 | 2019-03-15 | 新生抗原的鉴定方法 |
| CN202080008090.2A Active CN113316818B (zh) | 2019-03-15 | 2020-03-13 | 新生抗原的鉴定方法 |
Family Applications Before (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN201910198582.1A Pending CN111696628A (zh) | 2019-03-15 | 2019-03-15 | 新生抗原的鉴定方法 |
Country Status (2)
| Country | Link |
|---|---|
| CN (2) | CN111696628A (zh) |
| WO (1) | WO2020187143A1 (zh) |
Citations (8)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US20170016075A1 (en) * | 2015-07-14 | 2017-01-19 | Personal Genome Diagnostics, Inc. | Neoantigen analysis |
| WO2017024006A1 (en) * | 2015-08-03 | 2017-02-09 | The Johns Hopkins University | Personalized, allogeneic cell therapy of cancer |
| US20170199961A1 (en) * | 2015-12-16 | 2017-07-13 | Gritstone Oncology, Inc. | Neoantigen Identification, Manufacture, and Use |
| CN107636162A (zh) * | 2015-06-01 | 2018-01-26 | 加利福尼亚技术学院 | 用针对特定群体的抗原筛选t细胞的组合物和方法 |
| CN107704727A (zh) * | 2017-11-03 | 2018-02-16 | 杭州风起智能科技有限公司 | 基于肿瘤新抗原特征值的新抗原活性预测和排序方法 |
| CN108388773A (zh) * | 2018-02-01 | 2018-08-10 | 杭州纽安津生物科技有限公司 | 一种肿瘤新生抗原的鉴定方法 |
| CN108491689A (zh) * | 2018-02-01 | 2018-09-04 | 杭州纽安津生物科技有限公司 | 基于转录组的肿瘤新抗原鉴定方法 |
| WO2018183544A1 (en) * | 2017-03-31 | 2018-10-04 | Dana-Farber Cancer Institute, Inc. | Method for identification of retained intron tumor neoantigens from patient transcriptome |
Family Cites Families (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN108796055B (zh) * | 2018-06-12 | 2022-04-08 | 深圳裕策生物科技有限公司 | 基于二代测序的肿瘤新生抗原检测方法、装置和存储介质 |
| CN109021062B (zh) * | 2018-08-06 | 2021-08-20 | 倍而达药业（苏州）有限公司 | 一种肿瘤新抗原的筛选方法 |
-
2019
- 2019-03-15 CN CN201910198582.1A patent/CN111696628A/zh active Pending
-
2020
- 2020-03-13 WO PCT/CN2020/079131 patent/WO2020187143A1/zh active Application Filing
- 2020-03-13 CN CN202080008090.2A patent/CN113316818B/zh active Active
Patent Citations (9)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN107636162A (zh) * | 2015-06-01 | 2018-01-26 | 加利福尼亚技术学院 | 用针对特定群体的抗原筛选t细胞的组合物和方法 |
| US20170016075A1 (en) * | 2015-07-14 | 2017-01-19 | Personal Genome Diagnostics, Inc. | Neoantigen analysis |
| WO2017024006A1 (en) * | 2015-08-03 | 2017-02-09 | The Johns Hopkins University | Personalized, allogeneic cell therapy of cancer |
| US20170199961A1 (en) * | 2015-12-16 | 2017-07-13 | Gritstone Oncology, Inc. | Neoantigen Identification, Manufacture, and Use |
| CN108601731A (zh) * | 2015-12-16 | 2018-09-28 | 磨石肿瘤生物技术公司 | 新抗原的鉴别、制造及使用 |
| WO2018183544A1 (en) * | 2017-03-31 | 2018-10-04 | Dana-Farber Cancer Institute, Inc. | Method for identification of retained intron tumor neoantigens from patient transcriptome |
| CN107704727A (zh) * | 2017-11-03 | 2018-02-16 | 杭州风起智能科技有限公司 | 基于肿瘤新抗原特征值的新抗原活性预测和排序方法 |
| CN108388773A (zh) * | 2018-02-01 | 2018-08-10 | 杭州纽安津生物科技有限公司 | 一种肿瘤新生抗原的鉴定方法 |
| CN108491689A (zh) * | 2018-02-01 | 2018-09-04 | 杭州纽安津生物科技有限公司 | 基于转录组的肿瘤新抗原鉴定方法 |
Non-Patent Citations (2)
| Title |
|---|
| JEANNE MENEZ-JAMET等: "Optimized tumor cryptic peptides: the basis for universal neoantigen- like tumor vaccines", ANNALS OF TRANSLATIONAL MEDICINE, vol. 14, no. 4, 22 April 2016 (2016-04-22), pages 1 - 11 * |
| 高志博等: "肿瘤精准免疫治疗与基因检测", 生物产业技术, vol. 02, 28 February 2017 (2017-02-28), pages 27 - 33 * |
Also Published As
| Publication number | Publication date |
|---|---|
| WO2020187143A1 (zh) | 2020-09-24 |
| CN111696628A (zh) | 2020-09-22 |
| CN113316818B (zh) | 2024-04-02 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP7530455B2 (ja) | 新生抗原の特定、製造、及び使用 | |
| EP2872653B1 (en) | Personalized cancer vaccines and adoptive immune cell therapies | |
| TWI765875B (zh) | 新抗原辨識、製造及用途 | |
| CN108796055B (zh) | 基于二代测序的肿瘤新生抗原检测方法、装置和存储介质 | |
| JP7034931B2 (ja) | ネオエピトープのウイルス送達のための改善された組成物および方法ならびにその使用 | |
| JP2019513021A (ja) | ネオエピトープ提示のための配列の配置および配列 | |
| JP2019511907A (ja) | 癌免疫療法の治療標的としての患者特異的ネオエピトープのハイスループット同定 | |
| KR20240023699A (ko) | 바이러스성 암 네오에피토프를 위한 조성물 및 방법 | |
| TW201908491A (zh) | 腫瘤抗原性加工和呈遞 | |
| US20210284738A1 (en) | Ranking system for immunogenic cancer-specific epitopes | |
| US20190287656A1 (en) | Viral neoepitopes and uses thereof | |
| CN113316818B (zh) | 新生抗原的鉴定方法 | |
| EP4419716A1 (en) | Cancer neoantigens | |
| US20220296642A1 (en) | Methods of Making Therapeutic T Lymphocytes | |
| US20230197192A1 (en) | Selecting neoantigens for personalized cancer vaccine | |
| EA046410B1 (ru) | Иммуногенетическая скрининговая проба на рак |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| PB01 | Publication | ||
| PB01 | Publication | ||
| SE01 | Entry into force of request for substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| TA01 | Transfer of patent application right |
Effective date of registration: 20220816 Address after: Unit 202-1, No. 817, Lianting Road, Xiang'an District, Xiamen City, Fujian Province Applicant after: Trace Biomedical Technology (Xiamen) Co., Ltd. Address before: 14 / F, far east development building, 121 Des Voeux Road Central, Hong Kong, China Applicant before: Mark Zhun Biotechnology Co.,Ltd. |
|
| TA01 | Transfer of patent application right | ||
| GR01 | Patent grant | ||
| GR01 | Patent grant |